CN107913265A - Isovitexin is preparing the application in treating medicine for nasopharyngeal - Google Patents
Isovitexin is preparing the application in treating medicine for nasopharyngeal Download PDFInfo
- Publication number
- CN107913265A CN107913265A CN201610875278.2A CN201610875278A CN107913265A CN 107913265 A CN107913265 A CN 107913265A CN 201610875278 A CN201610875278 A CN 201610875278A CN 107913265 A CN107913265 A CN 107913265A
- Authority
- CN
- China
- Prior art keywords
- isovitexin
- nasopharyngeal
- medicine
- nasopharyngeal carcinoma
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses Isovitexin to prepare the application in treating medicine for nasopharyngeal, belongs to technical field of new application of medicine.The present invention is evaluated by external MTT antineoplastic activity and found, growths of the Isovitexin to human nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and CNE1 also has significant inhibitory action.Therefore, Isovitexin can be used to prepare anti-nasopharyngeal carcinoma medicine, have good development prospect.Belong to first public for purposes of the Isovitexin of the present invention in treatment medicine for nasopharyngeal is prepared, and it is unexpectedly strong for the inhibitory activity of nasopharyngeal carcinoma cell.
Description
Technical field
The present invention relates to the new application of compound Isovitexin, more particularly to Isovitexin to prepare treatment nasopharyngeal carcinoma
Application in medicine.
Background technology
Cancer is one of disease maximum to human life and health harm, has substantial amounts of people to die of cancer every year.Anticancer
The research and development of medicine are always the hot spot of study of pharmacy.It is natural products or derivatives thereof to have 74% in antitumor drug, such as Japanese yew
Alcohol and its derivative are exactly the current clinically relatively good antitumor drug of application effect.Therefore, found from natural products anti-
Chemical compound for treating cancer or lead compound have great importance.
Compound Isovitexin of the present invention be one deliver within 2012 (Ebenezer de Mello Cruz,
et al.,Leishmanicidal activity of Cecropia pachystachya flavonoids:Arginase
inhibition and altered mitochondrial DNA arrangement.Phytochemistry,89(2013)
71-77.) noval chemical compound, the compound possess brand-new framework types (Ebenezer de Mello Cruz, et al.,
Leishmanicidal activity of Cecropia pachystachya flavonoids:Arginase
inhibition and altered mitochondrial DNA arrangement.Phytochemistry,89(2013)
71-77.), belong to first public for purposes of the Isovitexin of the present invention in treatment medicine for nasopharyngeal is prepared, by
In belonging to brand-new structure type, and it is unexpectedly strong for the inhibitory activity of nasopharyngeal carcinoma cell, and there is no by other
Compound provides the possibility of any enlightenment, possesses prominent substantive distinguishing features, while obvious with aobvious for the prevention of nasopharyngeal carcinoma
The progress of work.
The content of the invention
It is an object of the invention to not find its report with anti-nasopharyngeal carcinoma activity in being studied according to existing Isovitexin
The present situation in road, there is provided applications of the Isovitexin in anti-nasopharyngeal carcinoma medicine is prepared.
The compound Isovitexin, shown in structure such as formula (I)：
The Isovitexin is preparing the application in treating medicine for nasopharyngeal, and nasopharyngeal carcinoma cell is human nasopharyngeal carcinoma cell line
HNE1, HNE2, HONE1 and CNE1.
One kind treats medicine for nasopharyngeal, and adding auxiliary material by Isovitexin for active ingredient is prepared, and preparation method is
5 g of compound Isovitexin are taken, add 195 grams of dextrin, are mixed, conventional tablet presses are made 1000.
One kind treats medicine for nasopharyngeal, and adding auxiliary material by Isovitexin for active ingredient is prepared, and preparation method is
5 g of compound Isovitexin are taken, add 195 grams of starch, are mixed, it is encapsulated to be made 1000.
The present invention by external MTT antineoplastic activity evaluate find, Isovitexin to human nasopharyngeal carcinoma cell line HNE1,
The growth of HNE2, HONE1 and CNE1 also have significant inhibitory action, and the IC50 values for suppressing this 4 plants of cell growths are respectively
2.67 ± 0.76 μM, 1.56 ± 0.33 μM, 1.74 ± 0.51 μM and 1.45 ± 0.41 μM.Therefore, Isovitexin can be used to make
Standby anti-nasopharyngeal carcinoma medicine, has good development prospect.
Belong to first public for purposes of the Isovitexin of the present invention in treatment medicine for nasopharyngeal is prepared, by
Belong to brand-new framework types in framework types, and it is unexpectedly strong for the inhibitory activity of nasopharyngeal carcinoma cell, does not deposit
The possibility of any enlightenment is being provided by other compounds, is possessing prominent substantive distinguishing features, while show for the prevention of nasopharyngeal carcinoma
So there is significant progress.
The present invention is described in further detail by the following examples, but protection scope of the present invention is from specific reality
Any restrictions of example are applied, but are defined in the claims.
Embodiment
The preparation method of compound Isovitexin involved in the present invention is referring to document (Ebenezer de Mello
Cruz, et al., Leishmanicidal activity of Cecropia pachystachya flavonoids:
Arginase inhibition and altered mitochondrial DNA arrangement.Phytochemistry,
89(2013)71–77.)
The present invention is described in further detail by the following examples, but protection scope of the present invention is from specific reality
Any restrictions of example are applied, but are defined in the claims.
Embodiment 1：The preparation of compound Isovitexin tablets involved in the present invention：
5 g of compound Isovitexin are taken, add 195 grams of dextrin, are mixed, conventional tablet presses are made 1000.
Embodiment 2：The preparation of compound Isovitexin capsules involved in the present invention：
5 g of compound Isovitexin are taken, add 195 grams of starch, are mixed, it is encapsulated to be made 1000.
Its pharmaceutical activity is further illustrated below by pharmacodynamic experiment.
Experimental example：Growth inhibition effects of the compound Isovitexin to human nasopharyngeal carcinoma cell line is evaluated using mtt assay
1. method：Cell in growth logarithmic phase：Human nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and CNE1 (purchase
From Chinese Academy of Sciences's cell bank) with 1.5 × 104Concentration kind is in 96 orifice plates.Original culture is sucked after cell culture 24h is adherent
Base.Experiment is divided into blank control group, drug-treated group.Blank group replaces 1640 culture mediums containing 10% hyclone；At medicine
Reason group replaces the culture containing the Isovitexin that concentration is 100 μM, 50 μM, 10 μM, 1 μM, 0.1 μM, 0.01 μM and 0.001 μM
Base.After cultivating 48h, the MTT of concentration 5mg/mL is added, continues to be put in CO2Incubator culture 4h, inhales then along nutrient solution top
100 μ L of supernatant are removed, add 100 μ L DMSO, 10min is placed in dark place, and extinction is measured using microplate reader (Sunrise Products)
It is worth (wavelength 570nm), and cell survival is calculated according to light absorption value, each processing sets 6 repeating holes.Cell survival rate (%)
=Δ OD drug-treateds/Δ OD blank control × 100.
2. result：Growths of the Isovitexin to human nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and CNE1 has notable
Inhibitory action.The compound suppresses the IC50 values that human nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and CNE1 are grown
2.67 ± 0.76 μM, 1.56 ± 0.33 μM, 1.74 ± 0.51 μM and 1.45 ± 0.41 μM.
Shown by above-described embodiment, Isovitexin of the invention to human nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and
The growth of CNE1 has good inhibiting effect.Thus prove, Isovitexin of the invention has anti-nasopharyngeal carcinoma activity, can use
In preparation anti-nasopharyngeal carcinoma medicine.
Claims (4)
- Applications of the 1.Isovitexin in medicine for nasopharyngeal is treated, shown in the compound Isovitexin structures such as formula (I)：
- 2. applications of the Isovitexin as claimed in claim 1 in medicine for nasopharyngeal is treated, it is characterised in that nasopharyngeal carcinoma cell For people's nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and CNE1.
- 3. one kind treats medicine for nasopharyngeal, it is characterised in that is added as the Isovitexin described in claim 1 for active ingredient Auxiliary material is prepared, and preparation method adds 195 grams of dextrin, mix, Conventional compression mechanism to take 5 g of compound Isovitexin Into 1000.
- 4. one kind treats medicine for nasopharyngeal, it is characterised in that is added as the Isovitexin described in claim 1 for active ingredient Auxiliary material is prepared, and preparation method adds 195 grams of starch, mixing is encapsulated to be made to take 5 g of compound Isovitexin 1000.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610875278.2A CN107913265A (en) | 2016-10-08 | 2016-10-08 | Isovitexin is preparing the application in treating medicine for nasopharyngeal |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610875278.2A CN107913265A (en) | 2016-10-08 | 2016-10-08 | Isovitexin is preparing the application in treating medicine for nasopharyngeal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107913265A true CN107913265A (en) | 2018-04-17 |
Family
ID=61892142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610875278.2A Pending CN107913265A (en) | 2016-10-08 | 2016-10-08 | Isovitexin is preparing the application in treating medicine for nasopharyngeal |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107913265A (en) |
-
2016
- 2016-10-08 CN CN201610875278.2A patent/CN107913265A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107913265A (en) | Isovitexin is preparing the application in treating medicine for nasopharyngeal | |
| CN107865852A (en) | Apigenin is preparing the application in treating medicine for nasopharyngeal | |
| CN107913269A (en) | Isovitexin is preparing the application in treating uterine neck cancer drug | |
| CN107913281A (en) | Isovitexin is preparing the application in treating laryngeal cancer medicine | |
| CN107865860A (en) | Apigenin is preparing the application in treating uterine neck cancer drug | |
| CN107913280A (en) | Isovitexin is preparing the application in treating breast cancer medicines | |
| CN107913270A (en) | Isovitexin is preparing the application in treating bile duct cancer drug | |
| CN107865855A (en) | Apigenin is preparing the application in treating breast cancer medicines | |
| CN107865861A (en) | Apigenin is preparing the application in treating tongue cancer drug | |
| CN107837253A (en) | Isovitexin is preparing the application in treating rectum cancer drug | |
| CN107865856A (en) | Apigenin is preparing the application in treating rectum cancer drug | |
| CN107865835A (en) | Orientin is preparing the application in treating tongue cancer drug | |
| CN107865877A (en) | Orientin is preparing the application in treating prostate cancer medicine | |
| CN107913267A (en) | Isovitexin is preparing the application in treating blindgut cancer | |
| CN107865836A (en) | Orientin is preparing the application in treating ovarian cancer | |
| CN107865879A (en) | Orientin is preparing the application in treating skin cancer drug | |
| CN107837285A (en) | Isovitexin is preparing the application in treating tongue cancer drug | |
| CN107854459A (en) | Apigenin is preparing the application in treating bile duct cancer drug | |
| CN107837264A (en) | Apigenin is preparing the application in treating gastric cancer medicament | |
| CN107865838A (en) | Apigenin is preparing the application in treating laryngeal cancer medicine | |
| CN107865863A (en) | Apigenin is preparing the application in treating blindgut cancer | |
| CN107865839A (en) | Apigenin is preparing the application in treating endometrial cancer drug | |
| CN107854474A (en) | Orientin is preparing the application in treating kidney medicine | |
| CN107837251A (en) | Apigenin is preparing the application in treating pancreatic cancer drug | |
| CN106474102A (en) | Application in preparation treatment breast cancer medicines for the Fistulains B |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180417 |